Skip to main content
Displaying 1 - 10 of 10
Display:
12
24
48
Metabolism, Alcohol & Toxicity
6
Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022
View
Metabolism, Alcohol & Toxicity
6
Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022
View
Metabolism, Alcohol & Toxicity
6
Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022
View
Metabolism, Alcohol & Toxicity
6
Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022
View
Metabolism, Alcohol & Toxicity
6
Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022
View
Metabolism, Alcohol & Toxicity
6
Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy